Structure-Function Analysis of Phenylpiperazine Derivatives as Intestinal Permeation Enhancers

被引:19
作者
Fein, Katherine C. [1 ]
Lamson, Nicholas G. [1 ]
Whitehead, Kathryn A. [1 ,2 ]
机构
[1] Carnegie Mellon Univ, Dept Chem Engn, Pittsburgh, PA 15213 USA
[2] Carnegie Mellon Univ, Dept Biomed Engn, Pittsburgh, PA 15213 USA
基金
美国安德鲁·梅隆基金会;
关键词
1-phenylpiperazine; Caco-2; oral delivery; permeation enhancer; piperazine derivatives; TIGHT JUNCTIONS; ORAL DELIVERY; SALMON-CALCITONIN; INSULIN DELIVERY; DRUG-DELIVERY; MACROMOLECULES; PERMEABILITY; BARRIER; MODEL; PH;
D O I
10.1007/s11095-017-2149-8
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A major obstacle preventing oral administration of macromolecular therapeutics is poor absorption across the intestinal epithelium into the bloodstream. One strategy to improve transport across this barrier is the use of chemical permeation enhancers. Several molecular families with permeation enhancing potential have been identified previously, including piperazines. In particular, 1-phenylpiperazine has been shown to enhance transepithelial transport with minimal cytotoxicity compared to similarly effective molecules. To better understand how the chemistry of 1-phenylpiperazine affects its utility as an intestinal permeation enhancer, this study examined a small library of 13 derivatives of 1-phenylpiperazine. The efficacy and cytotoxicity of 13 phenylpiperazine compounds were assessed in a Caco-2 model of the intestinal epithelium. Efficacy was measured using the paracellular diffusion marker calcein as well as by immunostaining and confocal imaging of Caco-2 monolayers. Of the 13 derivatives, two enhanced the permeability of the fluorescent marker calcein over 100-fold. It was found that hydroxyl or primary amine substitutions on the phenyl ring significantly increased toxicity, while aliphatic substitutions resulted in efficacy and toxicity profiles comparable to 1-phenylpiperazine. Several potent derivatives, including 1-methyl-4-phenylpiperazine and 1-(4-methylphenyl)piperazine, displayed lower toxicity than 1-phenylpiperazine, suggesting promise in future applications.
引用
收藏
页码:1320 / 1329
页数:10
相关论文
共 22 条
  • [1] EPITHELIAL TRANSPORT OF DRUGS IN CELL-CULTURE .1. A MODEL FOR STUDYING THE PASSIVE DIFFUSION OF DRUGS OVER INTESTINAL ABSORPTIVE (CACO-2) CELLS
    ARTURSSON, P
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1990, 79 (06) : 476 - 482
  • [2] Absorption Enhancers: Applications and Advances
    Aungst, Bruce J.
    [J]. AAPS JOURNAL, 2012, 14 (01): : 10 - 18
  • [3] An Assessment of the Permeation Enhancer, 1-phenyl-piperazine (PPZ), on Paracellular Flux Across Rat Intestinal Mucosae in Ussing Chambers
    Bzik, V. A.
    Brayden, D. J.
    [J]. PHARMACEUTICAL RESEARCH, 2016, 33 (10) : 2506 - 2516
  • [4] VIBRIO-CHOLERAE PRODUCES A 2ND ENTEROTOXIN, WHICH AFFECTS INTESTINAL TIGHT JUNCTIONS
    FASANO, A
    BAUDRY, B
    PUMPLIN, DW
    WASSERMAN, SS
    TALL, BD
    KETLEY, JM
    KAPER, JB
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (12) : 5242 - 5246
  • [5] Fuhrmann G, 2013, NAT CHEM, V5, P582, DOI [10.1038/nchem.1675, 10.1038/NCHEM.1675]
  • [6] In vivo evaluation of an oral salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix
    Guggi, D
    Kast, CE
    Bernkop-Schnürch, A
    [J]. PHARMACEUTICAL RESEARCH, 2003, 20 (12) : 1989 - 1994
  • [7] Mucoadhesive intestinal devices for oral delivery of salmon calcitonin
    Gupta, Vivek
    Hwang, Byeong Hee
    Lee, JooHee
    Anselmo, Aaron C.
    Doshi, Nishit
    Mitragotri, Samir
    [J]. JOURNAL OF CONTROLLED RELEASE, 2013, 172 (03) : 753 - 762
  • [8] A permeation enhancer for increasing transport of therapeutic macromolecules across the intestine
    Gupta, Vivek
    Hwang, Byeong Hee
    Doshi, Nishit
    Mitragotri, Samir
    [J]. JOURNAL OF CONTROLLED RELEASE, 2013, 172 (02) : 541 - 549
  • [9] The pH of Piperazine Derivative Solutions Predicts Their Utility as Transepithelial Permeation Enhancers
    Lamson, Nicholas G.
    Cusimano, Gabrielle
    Suri, Kanika
    Zhang, Anna
    Whitehead, Kathryn A.
    [J]. MOLECULAR PHARMACEUTICS, 2016, 13 (02) : 578 - 585
  • [10] Lindmark T, 1998, J PHARMACOL EXP THER, V284, P362